A surge in dealmaking that's helped Chinese biotech and healthcare firms sell their products globally faces several headwinds.
An employee works at Humanwell PuraCap Pharmaceuticals, a major Chinese softgel pharmaceutical manufacturer in Wuhan. Credit: FeatureChina via AP Images
Much as in the world of artificial intelligence, 2025 has begun on a high note for Chinese companies in biotech, with global interest in their work never greater.
An announcement from Keymed Biosciences on a deal made with Timberlyne Therapeutics. Credit: HKEX
But unlike in AI, where U.S. players are feeling the heat and seeking to block Chinese competitors from the market, Chinese biotech companies and their international counterparts have found ways to collaborate so both sides can
Exclusive longform investigative journalism, Q&As, news and analysis, and data on Chinese business elites and corporations. We publish China scoops you won't find anywhere else.
A weekly curated reading list on China from Andrew Peaple.
A daily roundup of China finance, business and economics headlines.
We offer discounts for groups, institutions and students. Go to our Subscriptions page for details.
The former Biden official and China scholar makes the case for the previous administration's approach and discusses why Beijing is content to watch the U.S. now dismantle its sources of strength
Navigate China's Business Landscape with Confidence.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OKPrivacy policy
